Scientific Reports · 2016 · 39 citations · 41 references
Life SciencesNeurobiologyNeuroscienceMolecular NeuroscienceNeuroplasticitySynaptic PlasticityDendritic Spine PlasticityLong-term PotentiationNeuroprotectionSynaptic DysfunctionSynaptic Strength RegulationSynaptic TransmissionCa1 FunctionDendritic SpinesHippocampal FunctionHippocampal Long-term PotentiationHippocampal Memory FunctionHippocampal PhysiologyHippocampal PlasticityLong-term Synaptic Plasticity
The pathogenesis of hypertension-related cognitive impairment has not been sufficiently clarified, new molecular targets are needed. p38 MAPK pathway plays an important role in hypertensive target organ damage. Activated p38 MAPK was seen in AD brain tissue. In this study, we found that long-term potentiation (LTP) of hippocampal CA1 was decreased, the density of the dendritic spines on the CA1 pyramidal cells was reduced, the p-p38 protein expression in hippocampus was elevated, and cognitive function was impaired in angiotensin II-dependent hypertensive C57BL/6 mice. In vivo, using a p38 heterozygous knockdown mice (p38(KI/+)) model, we showed that knockdown of p38 MAPK in hippocampus leads to the improvement of cognitive function and hippocampal synaptic plasticity in angiotensin II-dependent p38(KI/+) hypertensive mice. In vitro, LTP was improved in hippocampal slices from C57BL/6 hypertensive mice by treatment with p38MAPK inhibitor SKF86002. Our data demonstrated that p38 MAPK may be a potential therapeutic target for hypertension-related cognitive dysfunction.
41
2013 ESH/ESC Guidelines for the management of arterial hypertension
Giuseppe Mancia, Robert Fagard, Krzysztof Narkiewicz et al. · European Heart Journal · 2013 · 13.7K citations · Full text
2013 ESH/ESC Guidelines for the management of arterial hypertension
Giuseppe Mancia, Robert Fagard, Krzysztof Narkiewicz et al. · Journal of Hypertension · 2013 · 5.7K citations
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Neurology, Pharmacology +17
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Neurology, Neuroscience +14